U.S. markets open in 2 hours 40 minutes

PRA Health Sciences, Inc. (PRAH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
147.41-1.74 (-1.17%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close149.15
Open150.82
Bid0.00 x 800
Ask0.00 x 800
Day's Range147.00 - 150.82
52 Week Range58.67 - 155.00
Volume2,331,444
Avg. Volume459,596
Market Cap9.514B
Beta (5Y Monthly)1.25
PE Ratio (TTM)48.49
EPS (TTM)3.04
Earnings DateApr 28, 2021 - May 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est144.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
2% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. - PRAH
    PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of PRA Health Sciences, Inc. - PRAH

    Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating PRA Health Sciences, Inc. ("PRAH" or the "Company") (PRAH) relating to its proposed acquisition by ICON plc. Under the terms of the agreement, PRAH shareholders will receive 0.4125 shares of ICON stock and $80.00 in cash per share.

  • Moody's

    Pharmaceutical Research Associates, Inc. -- Moody's places PRA Holdings' ratings under review for upgrade on proposed acquisition by ICON Plc

    Rating Action: Moody's places PRA Holdings' ratings under review for upgrade on proposed acquisition by ICON PlcGlobal Credit Research - 26 Feb 2021New York, February 26, 2021 -- Moody's Investors Service ("Moody's") placed the ratings of PRA Holdings, Inc. and its subsidiaries (collectively "PRA") on review for upgrade following an announcement by ICON Plc (Baa3 RUR-down), that it has entered into a definitive agreement to acquire PRA. The ratings placed under review for upgrade include the Ba3 Corporate Family Rating, Ba3-PD Probability of Default Rating, and Ba3 senior secured credit facilities.

  • Moody's

    ICON Plc -- Moody's places ICON's rating under review for downgrade

    Rating Action: Moody's places ICON's rating under review for downgradeGlobal Credit Research - 26 Feb 2021Paris, February 26, 2021 -- Moody's Investors Service ("Moody's") has today placed ICON Plc's ("ICON" or "the company") Baa3 long-term issuer rating under review for downgrade. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.The ratings have been disclosed to the rated entity or its designated agent(s) and issued with no amendment resulting from that disclosure.These ratings are solicited.